Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 44 results.
User Information
Export Records
  1. 1.   Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
  2. Takebe, Naoko; Naqash, Abdul Rafeh; Coyne, Geraldine O'Sullivan; Kummar, Shivaani; Do, Khanh; Bruns, Ashley; Juwara,Lamin; Zlott, Jennifer; Rubinstein, Larry; Piekarz, Richard; Sharon, Elad; Streicher, Howard; Mittra, Arjun; Miller, Sarah B.; Ji,Jay; Wilsker,Deborah; Kinders,Robert; Parchment,Ralph; Chen,Li; Chang,Ting-Chia; Das,Biswajit; Mugundu, Ganesh; Doroshow, James H.; Chen, Alice P.
  3. CLINICAL CANCER RESEARCH. 2021, Apr 16; 27(14): 3834-3844.
  1. 2.   Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
  2. Kraft, Ira L.; Akshintala, Srivandana; Zhu, Yuelin; Lei, Haiyan; Derse-Anthony, Claudia; Dombi, Eva; Steinberg, Seth M.; Lodish, Maya; Waguespack, Steven G.; Kapustina, Oxana; Fox, Elizabeth; Balis, Frank M.; Merino, Maria J.; Meltzer, Paul S.; Glod, John W.; Shern, Jack F.; Widemann, Brigitte C.
  3. CLINICAL CANCER RESEARCH. 2018, Feb 15; 24(4): 753-765.
  1. 3.   Advances in using PARP inhibitors to treat cancer
  2. Kummar, S.; Chen, A.; Parchment, R. E.; Kinders, R. J.; Ji, J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Bmc Medicine. 2012, Mar; 10
  1. 4.   A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
  2. Kummar, S.; Ji, J. P.; Morgan, R.; Lenz, H. J.; Puhalla, S. L.; Belani, C. P.; Gandara, D. R.; Allen, D.; Kiesel, B.; Beumer, J. H.; Newman, E. M.; Rubinstein, L.; Chen, A.; Zhang, Y. P.; Wang, L. H.; Kinders, R. J.; Parchment, R. E.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Clinical Cancer Research. 2012, Mar; 18(6): 1726-1734.
  1. 5.   Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
  2. Ji, J. P.; Kinders, R. J.; Zhang, Y. P.; Rubinstein, L.; Kummar, S.; Parchment, R. E.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Plos One. 2011, Oct; 6(10): 8.
  1. 6.   Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA
  2. Soman, G.; Yang, X. Y.; Jiang, H. G.; Giardina, S.; Mitra, G.
  3. Journal of Immunological Methods. 2011, Oct; 373(1-2): 181-191.
  1. 7.   Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
  2. Kummar, S.; Chen, A.; Ji, J. P.; Zhang, Y. P.; Reid, J. M.; Ames, M.; Jia, L.; Weil, M.; Speranza, G.; Murgo, A. J.; Kinders, R.; Wang, L. H.; Parchment, R. E.; Carter, J.; Stotler, H.; Rubinstein, L.; Hollingshead, M.; Melillo, G.; Pommier, Y.; Bonner, W.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Cancer Research. 2011, Sep; 71(17): 5626-5634.
  1. 8.   Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
  2. Butterfield, L. H.; Palucka, A. K.; Britten, C. M.; Dhodapkar, M. V.; Hakansson, L.; Janetzki, S.; Kawakami, Y.; Kleen, T. O.; Lee, P. P.; Maccalli, C.; Maecker, H. T.; Maino, V. C.; Maio, M.; Malyguine, A.; Masucci, G.; Pawelec, G.; Potter, D. M.; Rivoltini, L.; Salazar, L. G.; Schendel, D. J.; Slingluff, C. L.; Song, W. R.; Stroncek, D. F.; Tahara, H.; Thurin, M.; Trinchieri, G.; van Der Burg, S. H.; Whiteside, T. L.; Wigginton, J. M.; Marincola, F.; Khleif, S.; Fox, B. A.; Disis, M. L.
  3. Clinical Cancer Research. 2011, May; 17(10): 3064-3076.
  1. 9.   Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC
  2. Stockwin, L. H.; Yu, S. X.; Borgel, S.; Hancock, C.; Wolfe, T. L.; Phillips, L. R.; Hollingshead, M. G.; Newton, D. L.
  3. International Journal of Cancer. 2010, Dec; 127(11): 2510-2519.
  1. 10.   Development of a Validated Immunofluorescence Assay for gamma H2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity
  2. Kinders, R. J.; Hollingshead, M.; Lawrence, S.; Ji, J. P.; Tabb, B.; Bonner, W. M.; Pommier, Y.; Rubinstein, L.; Evrard, Y. A.; Parchment, R. E.; Tomaszewski, J.; Doroshow, J. H.; Natl Canc Inst Phase 0 Clinical, T.
  3. Clinical Cancer Research. 2010, Nov; 16(22): 5447-5457.
  1. 11.   Plant Natural Products in Anticancer Drug Discovery
  2. Grothaus, P. G.; Cragg, G. M.; Newman, D. J.
  3. Current Organic Chemistry. 2010, Oct; 14(16): 1781-1791.
  1. 12.   The statistics of phase 0 trials
  2. Rubinstein, L. V.; Steinberg, S. M.; Kummar, S.; Kinders, R.; Parchment, R. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Statistics in Medicine. 2010, May; 29(10): 1072-1076.
  1. 13.   Probiotics: From Bench to Market
  2. Klein, M.; Sanders, M. E.; Duong, T.; Young, H. A.
  3. Probiotics: From Bench to Market. 2010; 1212 : E1-E14.
  1. 14.   Response: Re: Antitumor Efficacy Testing in Rodents
  2. Hollingshead, M. G.
  3. Journal of the National Cancer Institute. 2009 101(22): 1593-1594.
  1. 15.   Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
  2. Piekarz, R. L.; Frye, R.; Turner, M.; Wright, J. J.; Allen, S. L.; Kirschbaum, M. H.; Zain, J.; Prince, H. M.; Leonard, J. P.; Geskin, L. J.; Reeder, C.; Joske, D.; Figg, W. D.; Gardner, E. R.; Steinberg, S. M.; Jaffe, E. S.; Stetler-Stevenson, M.
  3. Journal of Clinical Oncology. 2009 27(32): 5410-5417.
  1. 16.   Incorporation of endothelial progenitor cells into the neovasculature of malignant glioma xenograft
  2. Zhang, H. R.; Chen, F. L.; Xu, C. P.; Ping, Y. F.; Wang, Q. L.; Liang, Z. Q.; Wang, J. M.; Bian, X. W.
  3. Journal of Neuro-Oncology. 2009 93(2): 165-174.
  1. 17.   The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiograpgy in central nervous system malignancy: A pilot study
  2. Neuwelt, E. A.; Varallyay, C. G.; Manninger, S.; Solymosi, D.; Haluska, M.; Hunt, M. A.; Nesbit, G.; Stevens, A.; Jerosch-Herold, M.; Jacobs, P. M.; Hoffman, J. M.
  3. Neurosurgery. 2007, Apr; 60(4): 601-611.
  1. 18.   Compressing drug development timelines in oncology using phase '0' trials
  2. Kummar, S.; Kinders, R.; Rubinstein, L.; Parchment, R. E.; Murgo, A. J.; Collins, J.; Pickeral, O.; Low, J.; Steinberg, S. M.; Gutierrez, M.; Yang, S.; Helman, L.; Wiltrout, R.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Nature Reviews Cancer. 2007, Feb; 7(2): 131-139.
  1. 19.   Elevated K-ras activity with cholestyramine and lovastatin, but not konjac mannan or niacin in lung - Importance of mouse strain
  2. Calvert, R. J.; Tepper, S.; Kammouni, W.; Anderson, L. M.; Kritchevsky, D.
  3. Biochemical Pharmacology. 2006, Dec; 72(12): 1749-1755.
  1. 20.   Antibody-based inhibitors of HIV infection
  2. Choudhry, V.; Zhang, M. Y.; Dimitrova, D.; Prabakaran, P.; Dimitrov, A. S.; Fouts, T. R.; Dimitrov, D. S.
  3. Expert Opinion on Biological Therapy. 2006, MAY; 6(5): 523-531.
  1. 21.   TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer
  2. Cretney, E.; Shanker, A.; Yagita, H.; Smyth, M. J.; Sayers, T. J.
  3. Immunology and Cell Biology. 2006, FEB; 84(1): 87-98.
  1. 22.   Novel human monoclonal antibodies to insulin-like growth factor (IGH)-II that potently inhibit the IGF receptor type I signal transduction function
  2. Feng, Y.; Zhu, Z. Y.; Xiao, X. D.; Choudhry, V.; Barrett, J. C.; Dimitrov, D. S.
  3. Molecular Cancer Therapeutics. 2006, JAN; 5(1): 114-120.
  1. 23.   Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: Implications for diagnostic and vaccine development
  2. Manimala, J. C.; Li, Z. T.; Jain, A.; VedBrat, S.; Gildersleeve, J. C.
  3. Chembiochem. 2005, DEC; 6(12): 2229-2241.
  1. 24.   Phase I trial of temozolomide plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
  2. Quinn, J. A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M. E.; Delaney, S. M.; Vredenburgh, J.; Rich, J.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Pegg, A. E.; Moschel, R. C.; Birch, R.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Dancey, J. E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S.
  3. Journal of Clinical Oncology. 2005, OCT 1; 23(28): 7178-7187.
  1. 25.   Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-4
  2. Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Hamel, E.; Schmidt, J. M.; Pettitt, R. K.
  3. Journal of Medicinal Chemistry. 2005, JUN 16; 48(12): 4087-4099.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel